《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2012年 > 10期

速效胰岛素类似物门冬胰岛素的临床研究进展——来自A1chieve研究的启示

来自:中国糖尿病资讯网  编辑:editor|点击数:|2012-10-24

  【提要】虽然血糖达标的重要意义在糖尿病管理过程中被反复强调,但A1chieve等研究的结果显示目前中国2型糖尿病患者的血糖控制现状普遍较差。这使得能够减少低血糖发生,兼顾理想的血糖控制和良好安全性的糖尿病治疗管理方式成为重中之重。本文综述了速效胰岛素类似物门冬胰岛素的临床研究进展;并综述了从一项全球性、大型非干预性研究—A1chieve研究中,进一步证实的门冬胰岛素的安全性和疗效结果。

  【关键词】 糖尿病,2型,门冬胰岛素,胰岛素类似物

  Latest advances of clinical research in fast acting insulin analogue insulin aspart: results from the A1chieve study. Mu Yiming Endocrinology department, Chinese PLA General Hospital

  【Summary】Althogh the importance of achieving HbA1c target has always been stressed in the management of diabetes mellitus, recent study results from the A1chieve study shows that delay in beggining or optimizing insulin therapy despite poor glycemic controal in Chinese patients with type 2 diabetes. Hence it is crucial to select a safe and effective treatment with low risk of hypoglyceamia to optimize individual glycaemic control. The key clinical researchs on insulin aspart were reviewed in this article. The latest results from a large scale multinational, non-interventional A1chieve study which shows insulin aspart is safe and effective in the routine clinical practice is also summarized.

  【Key words】 Diabetes mellitus,type 2; Insulin analogues, insulin aspart

上一篇:内皮微颗粒与糖尿病患者内皮功能障碍 下一篇:对C-肽生理作用的新认识与临床应用前景